Isabl provides a full genome and transcriptome analysis of tumor biopsies to identify cancer-associated mutations in every sample. This technology enhances biomarker discovery, enabling more accurate diagnoses for patients who do not benefit from traditional panel-based tests.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing panel-based diagnostic tests often fail to identify relevant cancer-associated mutations in tumor biopsies, leaving many patients without a clear diagnosis or optimal treatment plan. This limitation hinders comprehensive biomarker discovery and personalized cancer care.
Solution
Isabl provides a comprehensive genomic and transcriptomic analysis of tumor biopsies, enabling the identification of cancer-associated mutations in every sample. By analyzing the entire tumor genome and transcriptome, Isabl offers a more complete picture of the tumor's genetic makeup compared to traditional panel-based tests. This comprehensive approach enhances biomarker discovery, leading to more accurate diagnoses and potentially more effective treatment strategies for cancer patients. The Isabl GxT technology aims to make full genome testing a reality for all cancer patients.
Target Audience
The primary users are oncologists, pathologists, and researchers involved in cancer diagnosis and treatment who require comprehensive genomic information to guide clinical decision-making.
Features
- Full genome and transcriptome analysis of tumor biopsies
- Identification of cancer-associated mutations in every sample
- Comprehensive biomarker discovery
- FDA Breakthrough Device Designation